Shares of Halozyme Therapeutics, Inc. (HALO) were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year 2024 financial guidanceThe company also announced that it has entered into a new $250 million accelerated share repurchase program under the previously announced $750 million share repurchase program.HALO’s top line comprises product sales, royalty payments from Roche (RHHBY) for Phesgo and J&J (JNJ) for sub ...